LEXINGTON, Mass.--(BUSINESS WIRE)--Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has launched an initial public offering of 7,700,000 shares of its common stock. In addition, Translate Bio expects to grant the underwriters a 30-day option to purchase up to 1,155,000 additional shares of common stock at the public offering price, less the underwriting discount. All of the shares to be sold in the proposed offering will be offered by Translate Bio. The initial public offering price is expected to be between $12.00 and $14.00 per share. Translate Bio has applied to list the shares on the Nasdaq Global Market under the symbol “TBIO.”
Citigroup, Leerink Partners and Evercore ISI are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
A registration statement relating to the offering has been filed with the Securities and Exchange Commission but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Translate Bio
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.

